PriceTargets.com logo

Enlivex Therapeutics - ENLV Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $10.00
  • Forecasted Upside: 880.39%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 1 Strong Buy Ratings
$1.02 As of 03/28/2025 04:59 PM ET
▲ +0.01 (0.99%)

This chart shows the closing price for ENLV by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
FebMar$1.02Closing price on 03/29/25:
Get New Enlivex Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ENLV and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ENLV

Analyst Price Target is $10.00
▲ +880.39% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Enlivex Therapeutics in the last 3 months. The average price target is $10.00, with a high forecast of $13.00 and a low forecast of $7.00. The average price target represents a 880.39% upside from the last price of $1.02.

This chart shows the closing price for ENLV for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart
3/246/249/2412/243/254/26$0.60$3.70$6.80$9.90$13Closing price on 03/29/25: $1.02High$13.00Average$10.00Low$7.00




Current Consensus is Buy

The current consensus among 3 contributing investment analysts is to buy stock in Enlivex Therapeutics. This rating has held steady since November 2024, when it changed from a Strong Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/6/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/4/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/3/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/2/2024
  • 1 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/30/2024
  • 1 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/29/2024
  • 1 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/27/2025
  • 1 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/29/2025

Latest Recommendations

  • 1 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
3/24/2025HC WainwrightBoost TargetBuy ➝ Buy$6.00 ➝ $7.00
3/3/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$13.00 ➝ $13.00
2/7/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$13.00 ➝ $13.00
12/11/2024D. Boral CapitalReiterated RatingBuy ➝ Buy$13.00 ➝ $13.00
12/3/2024D. Boral CapitalReiterated RatingBuy ➝ Buy$13.00 ➝ $13.00
9/27/2024HC WainwrightReiterated RatingBuy ➝ Buy$6.00 ➝ $6.00
9/9/2024HC WainwrightReiterated RatingBuy ➝ Buy$6.00 ➝ $6.00
8/27/2024EF Hutton Acquisition Co. IUpgradeStrong-Buy
6/11/2024HC WainwrightLower TargetBuy ➝ Buy$7.00 ➝ $6.00
4/23/2024HC WainwrightReiterated RatingBuy ➝ Buy$7.00
4/12/2024HC WainwrightLower TargetBuy ➝ Buy$12.00 ➝ $7.00
9/25/2023HC WainwrightLower TargetBuy ➝ Buy$15.00 ➝ $12.00
8/1/2023HC WainwrightReiterated RatingBuy ➝ Buy$15.00
4/5/2023HC WainwrightReiterated RatingBuy$15.00
2/24/2023HC WainwrightReiterated RatingBuy$15.00
5/2/2022HC WainwrightLower Target$33.00 ➝ $15.00
10/5/2021HC WainwrightReiterated RatingBuy$33.00
8/10/2021HC WainwrightReiterated RatingBuy$33.00
8/3/2021HC WainwrightReiterated RatingBuy$33.00
7/14/2021HC WainwrightReiterated RatingBuy$33.00
6/7/2021HC WainwrightReiterated RatingBuy$33.00
3/2/2021HC WainwrightBoost TargetPositive ➝ Buy$22.00 ➝ $33.00
10/2/2020HC WainwrightReiterated RatingBuy
9/8/2020HC WainwrightReiterated RatingBuy
7/21/2020HC WainwrightReiterated RatingBuy$22.00
5/8/2020HC WainwrightReiterated RatingBuy
(Data available from 3/30/2020 forward)

News Sentiment Rating

0.41 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/31/2024
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/30/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/30/2024
  • 1 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/29/2024
  • 1 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/29/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/28/2025
  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
2/27/2025
  • 3 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/29/2025

Current Sentiment

  • 3 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Enlivex Therapeutics logo
Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.
Read More

Today's Range

Now: $1.02
Low: $1.00
High: $1.04

50 Day Range

MA: $1.09
Low: $0.98
High: $1.22

52 Week Range

Now: $1.02
Low: $0.81
High: $4.59

Volume

49,313 shs

Average Volume

155,084 shs

Market Capitalization

$21.83 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.11

Frequently Asked Questions

What sell-side analysts currently cover shares of Enlivex Therapeutics?

The following sell-side analysts have issued stock ratings on Enlivex Therapeutics in the last twelve months: D. Boral Capital, EF Hutton Acquisition Co. I, and HC Wainwright.
View the latest analyst ratings for ENLV.

What is the current price target for Enlivex Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Enlivex Therapeutics in the last year. Their average twelve-month price target is $10.00, suggesting a possible upside of 880.4%. D. Boral Capital has the highest price target set, predicting ENLV will reach $13.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $7.00 for Enlivex Therapeutics in the next year.
View the latest price targets for ENLV.

What is the current consensus analyst rating for Enlivex Therapeutics?

Enlivex Therapeutics currently has 2 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ENLV will outperform the market and that investors should add to their positions of Enlivex Therapeutics.
View the latest ratings for ENLV.

What other companies compete with Enlivex Therapeutics?

Other companies that are similar to Enlivex Therapeutics include Invivyd, SELLAS Life Sciences Group, Alpha Cognition, Adlai Nortye and Rani Therapeutics. Learn More about companies similar to Enlivex Therapeutics.

How do I contact Enlivex Therapeutics' investor relations team?

Enlivex Therapeutics' physical mailing address is 37 DEREH MENACHEM BEGIN ST. 15TH FLOOR, TEL AVIV L3, 6522042. The company's listed phone number is (728) 662-3301 and its investor relations email address is info@enlivex.com. The official website for Enlivex Therapeutics is www.enlivex.com. Learn More about contacing Enlivex Therapeutics investor relations.





Receive Enlivex Therapeutics News & Ratings Daily
Sign up to receive the latest news and ratings for Enlivex Therapeutics and its competitors with PriceTargets.com’s free daily newsletter.